Plymouth Hospitals NHS Trust has been chosen to co-ordinate the national programme for the training of existing consultants in advanced keyhole surgery for the treatment of bowel cancer. The Department of Health has appointed Consultant General Surgeon, Mr Mark Coleman as the National Clinical Lead for the Laparoscopic Colorectal Cancer Surgery Training Programme. Continue reading ...
Teens continue to put themselves at unnecessary risk of skin cancer by spending excessive time in the sun and forgetting to protect themselves, according to new Cancer Council research. Findings from the Cancer Council's National Sun Protection Survey released today show teens spend an average of two hours (1hr 51mins) in the sun during peak UV, with almost a third who get sunburnt saying they "forgot" to protect themselves. Continue reading ...
Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has progressed another of its oncology compounds into pivotal phase III clinical development. Continue reading ...
In the November 15th issue of G&D, Dr. Kenneth Dorshkind and colleagues at the David Geffen School of Medicine (UCLA) have identified two genes - p16(Ink4a) and Arf - that sensitize lymphoid progenitor cells to the effects of aging, and confer resistance to leukemogenesis. Hematopoiesis (the development of blood cells) entails two main pathways: myelopoiesis (the formation of the red and white myeloid cells) and lymphopoiesis (the formation of B- and T-cells). Continue reading ...
Cytopia Limited (ASX:CYT) has commenced dosing patients in its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, to treat glioblastoma multiforme (GBM), an aggressive brain cancer. The GBM clinical trial is the company's first Phase II efficacy study in highly vascular, solid tumour indications and the first time CYT997 is being investigated in a tumour of the central nervous system. Continue reading ...
A new piece of medical technology unveiled at the National Physical Laboratory (NPL) will help improve the success rates of radiotherapy cancer treatments. The new clinical electron linear accelerator (linac) will help ensure patients are treated with accurate doses of radiation. Radiotherapy treats cancer, by using ionising radiation such as high-energy X-rays or electron beams, to destroy cancer cells. Continue reading ...
Propelled by advances in molecular biology, the treatment of colorectal cancer is on the verge of dramatic change and a promising future as innovative vaccines will replace chemotherapy. According to a new report from Kalorama Information, "Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis," this market, lead by OncoVAX, is poised for unprecedented growth, creating countless opportunities for market participants. Continue reading ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment